View All Documents & Correspondence
Fgf21 Derivatives And Uses Thereof
Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167 169 170 171 172 173 174 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients as well as the medical use of the FGF21 derivatives.
Notices, Deadlines & Correspondence
Patent Information
Applicants
NOVO NORDISK A/S
Inventors
1. WIECZOREK Birgit
2. TAGMOSE Tina Møller
3. SASS ØRUM Kristian
4. ANDERSEN Birgitte
5. OLSEN Jørgen
Specification
15. A derivative according to any one of claims 1-14 for use as a medicament.
16. A derivative according to any one of claims 1-14 for use in a method of treatment and/or prevention of any one of all forms of diabetes and related diseases, such as obesity, eating disorders, cardiovascular diseases, diabetic complications; and/or for
• improving lipid parameters, improving p-cell function; and/or for delaying or preventing diabetic disease progression; and/or for of treatment and/or prevention of hepatic steatosis and non-alcoholic fatty liver disease (NAFLD).
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | Sequence listing(PDF) [20-06-2017(online)].pdf | 2017-06-20 |
| 2 | Sequence listing [20-06-2017(online)].pdf | 2017-06-20 |
| 3 | Priority Document [20-06-2017(online)].pdf | 2017-06-20 |
| 4 | Power of Attorney [20-06-2017(online)].pdf | 2017-06-20 |
| 5 | Form 5 [20-06-2017(online)].pdf | 2017-06-20 |
| 6 | Form 3 [20-06-2017(online)].pdf | 2017-06-20 |
| 7 | Form 1 [20-06-2017(online)].pdf | 2017-06-20 |
| 8 | Description(Complete) [20-06-2017(online)].pdf_37.pdf | 2017-06-20 |
| 9 | Description(Complete) [20-06-2017(online)].pdf | 2017-06-20 |
| 10 | 201747021545.pdf | 2017-06-21 |
| 11 | Correspondence by Agent_Form5-Sequence listing-PA_23-06-2017.pdf | 2017-06-23 |
| 12 | 201747021545-FORM 18 [21-08-2017(online)].pdf | 2017-08-21 |
| 13 | 201747021545-Proof of Right (MANDATORY) [07-12-2017(online)].pdf | 2017-12-07 |
| 14 | Correspondence by Agent_Form1_11-12-2017.pdf | 2017-12-11 |
| 15 | 201747021545-FORM 3 [20-12-2017(online)].pdf | 2017-12-20 |
| 16 | 201747021545-FORM 3 [20-06-2018(online)].pdf | 2018-06-20 |
| 17 | 201747021545-FORM 3 [14-12-2018(online)].pdf | 2018-12-14 |
| 18 | 201747021545-FORM 3 [11-06-2019(online)].pdf | 2019-06-11 |
| 19 | 201747021545-FORM 3 [06-12-2019(online)].pdf | 2019-12-06 |
| 20 | 201747021545-FORM-26 [18-12-2019(online)].pdf | 2019-12-18 |
| 21 | 201747021545-FER.pdf | 2020-01-23 |
| 22 | 201747021545-Information under section 8(2) [01-06-2020(online)].pdf | 2020-06-01 |
| 23 | 201747021545-FORM 3 [01-06-2020(online)].pdf | 2020-06-01 |
| 24 | 201747021545-OTHERS [17-07-2020(online)].pdf | 2020-07-17 |
| 25 | 201747021545-FER_SER_REPLY [17-07-2020(online)].pdf | 2020-07-17 |
| 26 | 201747021545-COMPLETE SPECIFICATION [17-07-2020(online)].pdf | 2020-07-17 |
| 27 | 201747021545-CLAIMS [17-07-2020(online)].pdf | 2020-07-17 |
| 28 | 201747021545-Annexure [17-07-2020(online)].pdf | 2020-07-17 |
| 29 | 201747021545-ABSTRACT [17-07-2020(online)].pdf | 2020-07-17 |
| 30 | 201747021545-Information under section 8(2) [27-11-2020(online)].pdf | 2020-11-27 |
| 31 | 201747021545-FORM 3 [27-11-2020(online)].pdf | 2020-11-27 |
| 32 | 201747021545-Information under section 8(2) [19-05-2021(online)].pdf | 2021-05-19 |
| 33 | 201747021545-FORM 3 [19-05-2021(online)].pdf | 2021-05-19 |
| 34 | 201747021545-Information under section 8(2) [12-08-2021(online)].pdf | 2021-08-12 |
| 35 | 201747021545-FORM 3 [12-08-2021(online)].pdf | 2021-08-12 |
| 36 | 201747021545-US(14)-HearingNotice-(HearingDate-22-02-2022).pdf | 2022-01-07 |
| 37 | 201747021545-Information under section 8(2) [09-02-2022(online)].pdf | 2022-02-09 |
| 38 | 201747021545-FORM 3 [09-02-2022(online)].pdf | 2022-02-09 |
| 39 | 201747021545-Correspondence to notify the Controller [15-02-2022(online)].pdf | 2022-02-15 |
| 40 | 201747021545-Information under section 8(2) [03-03-2022(online)].pdf | 2022-03-03 |
| 41 | 201747021545-FORM 3 [03-03-2022(online)].pdf | 2022-03-03 |
| 42 | 201747021545-Written submissions and relevant documents [08-03-2022(online)].pdf | 2022-03-08 |
| 43 | 201747021545-Annexure [08-03-2022(online)].pdf | 2022-03-08 |
| 44 | 201747021545-PatentCertificate31-05-2022.pdf | 2022-05-31 |
| 45 | 201747021545-IntimationOfGrant31-05-2022.pdf | 2022-05-31 |
| 46 | 201747021545-PROOF OF ALTERATION [21-12-2022(online)].pdf | 2022-12-21 |
| 47 | 201747021545-FORM-26 [12-01-2023(online)].pdf | 2023-01-12 |
| 48 | 201747021545-RELEVANT DOCUMENTS [11-09-2023(online)].pdf | 2023-09-11 |
| 49 | 201747021545-FORM-26 [27-12-2023(online)].pdf | 2023-12-27 |
| 50 | 201747021545-FORM 4 [29-12-2023(online)].pdf | 2023-12-29 |
Search Strategy
| 1 | strategy_545_20-01-2020.pdf |